Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 21 May 2024Published: 28 May 2014
Cladribine for treating relapsing–remitting multiple sclerosis (TA616)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 21 May 2024Published: 19 December 2019
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis (TA127)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 21 May 2024Published: 22 August 2007
Multiple sclerosis in adults: management (NG220)Product type:GuidanceProgramme:NICE guidelinePublished: 22 June 2022
Diroximel fumarate for treating relapsing–remitting multiple sclerosis (TA794)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 June 2022
Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 February 2022
Ozanimod for treating relapsing–remitting multiple sclerosis (TA706)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 June 2021
Ofatumumab for treating relapsing multiple sclerosis (TA699)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 May 2021
Siponimod for treating secondary progressive multiple sclerosis (TA656)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 November 2020
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 February 2020
Ocrelizumab for treating primary progressive multiple sclerosis (TA585)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 June 2019
Percutaneous venoplasty for chronic cerebrospinal venous insufficiency in multiple sclerosis (IPG640)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 30 January 2019
Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 July 2018
Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 June 2018
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 August 2014
Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 June 2014Published: 22 January 2014
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 April 2012
Functional electrical stimulation for drop foot of central neurological origin (IPG278)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 28 January 2009
Deep brain stimulation for tremor and dystonia (excluding Parkinson's disease) (IPG188)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 August 2006
icobrain ms for active relapsing–remitting multiple sclerosis (MIB291)Product type:AdviceProgramme:Medtech innovation briefingPublished: 29 March 2022
ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)Product type:AdviceProgramme:Medtech innovation briefingPublished: 11 March 2016